Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gradual vs. Abrupt Cessation for Smoking
NCT00297492Phase 2Completed
- Sponsor
- The University of Vermont
- Start
- Jan 2006
- Primary completion
- Feb 2008
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nicotine polacrilex in Tobacco Use Disorder (TUD) (3 arms), sponsored by The University of Vermont. Primary endpoint: Number of Participants With Prolonged Abstinence Through 6 Months Verified by Carbon Monoxide Measurement. Started Jan 2006; status: completed.
02
Drugs
nicotine polacrilex
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT00297492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297492.